In vivo, a study illustrated that combination therapy of miR-146a antagomiR (anti-miR-146a) and anti-PD-1 antibody exhibited better performance in shrinking melanoma tumors and improving survival rate compared to solo anti-PD-1 treatment [124]. The gene discussed is PDCD1; the disease is melanoma.